We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.81B
AUM Growth
+$244M
Cap. Flow
-$21.2M
Cap. Flow %
-0.56%
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35

Top Buys

Rank Stock Value
1
VRCA icon
Verrica Pharmaceuticals
VRCA
+$66.8M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$63.1M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$56.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$31.2M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$107M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$34.2M
4
ANAB icon
AnaptysBio
ANAB
+$24.7M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Industrials 0.65%
3 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVC
76
DELISTED
Invacare Corporation
IVC
$3.72M 0.1%
200,000
– –
ATNX
77
DELISTED
Athenex, Inc. Common Stock
ATNX
$3.54M 0.09%
9,500
– –
STIM icon
78
Neuronetics
STIM
$127M
$3.34M 0.09%
+125,500
New +$3.41M
ODT
79
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$3.31M 0.09%
150,000
– –
NVTR
80
DELISTED
Nuvectra Corporation Common Stock
NVTR
$3.27M 0.09%
159,466
-225,134
-59% -$3.8M
ALNA
81
DELISTED
Allena Pharmaceuticals
ALNA
$3.26M 0.09%
250,000
– –
GERN icon
82
Geron
GERN
$898M
$2.92M 0.08%
+2,550,000
New +$9.74M
ACHN
83
DELISTED
Achillion Pharmaceuticals
ACHN
$2.83M 0.07%
1,000,000
– –
KNSA icon
84
Kiniksa Pharmaceuticals
KNSA
$6.23B
$1.93M 0.05%
+111,111
New +$2.01M
EIGR
85
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.92M 0.05%
5,256
– –
AGRX
86
DELISTED
Agile Therapeutics
AGRX
$1.74M 0.05%
1,765
– –
SBBP
87
DELISTED
Strongbridge Biopharma plc.
SBBP
$1.65M 0.04%
275,000
– –
EVH icon
88
Evolent Health
EVH
$371M
$1.47M 0.04%
+70,000
New +$1.32M
FRTX
89
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.31M 0.03%
3,628
– –
STLA icon
90
Stellantis
STLA
$17.4B
$1.17M 0.03%
62,000
– –
SNDA icon
91
Sonida Senior Living
SNDA
$1.93B
$1.07M 0.03%
6,678
– –
ABEO icon
92
Abeona Therapeutics
ABEO
$355M
$954K 0.03%
2,386
-37,540
-94% -$16.4M
TRHC
93
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$936K 0.02%
14,663
– –
ONC
94
BeOne Medicines Ltd
ONC
$33.9B
$876K 0.02%
5,700
– –
ADYX
95
DELISTED
Adynxx Inc
ADYX
$867K 0.02%
70,566
– –
RACE icon
96
Ferrari
RACE
$67.8B
$837K 0.02%
6,200
– –
TARA icon
97
Protara Therapeutics
TARA
$214M
$819K 0.02%
8,353
– –
GRDX
98
GridAI Technologies Corp
GRDX
$18.3M
$730K 0.02%
2
– –
ARRY
99
DELISTED
Array Biopharma Inc
ARRY
$673K 0.02%
40,133
– –
PTCT icon
100
PTC Therapeutics
PTCT
$6.18B
$653K 0.02%
19,367
-280,633
-94% -$8.75M
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
  • Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
  • Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
  • Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
  • Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.